DOCSLIB.ORG

Targeting CD38 Enhances the Antileukemic Activity of Ibrutinib In

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Targeting CD38 Enhances the Antileukemic Activity of Ibrutinib In Published OnlineFirst April 2, 2019; DOI: 10.1158/1078-0432.CCR-18-3412 Translational Cancer Mechanisms and Therapy Clinical Cancer Research Targeting CD38 Enhances the Antileukemic Activity of Ibrutinib in Chronic Lymphocytic Leukemia Alak Manna1, Sonikpreet Aulakh2, Prachi Jani2, Salman Ahmed2, Sharoon Akhtar1, Marie Coignet3, Michael Heckman4, Zahara Meghji2, Kirtipal Bhatia2, Aarushi Sharma1, TaimurSher2,Victoria Alegria2, Fabio Malavasi5, Eduardo N.Chini6, Asher Chanan-Khan1,2,7, Sikander Ailawadhi2, and Aneel Paulus1,2 Abstract Purpose: CD38 has emerged as a high-impact thera- measured via immunoblotting of Lyn, Syk, BTK, PLCg2, peutic target in multiple myeloma, with the approval ERK1/2, and AKT. of daratumumab (anti-CD38 mAb). The clinical impor- Results: In addition to immune-effector mechanisms; tance of CD38 in patients with chronic lymphocytic daratumumab also induced direct apoptosis of primary leukemia (CLL) has been known for over 2 decades, CLL cells, which was partially dependent on FcgR cross-link- although it's relevance as a therapeutic target in CLL re- ing. For the first time, we demonstrated the influence of mains understudied. CD38 on BCR signaling where interference of CD38 down- Experimental Design: We investigated the biological regulated Syk, BTK, PLCg2, ERK1/2, and AKT; effects that effects and antitumor mechanisms engaged by daratumu- were further enhanced by addition of ibrutinib. In comparison mab in primary CLL cells. Besides its known immune- to single-agent treatment, the combination of ibrutinib and effector mechanisms (antibody-dependent cell-mediated daratumumab resulted in significantly enhanced anti-CLL cytotoxicity, complement-dependent death, and anti- activity in vitro and significantly decreased tumor growth and body-dependent cellular phagocytosis), we also measured prolonged survival in the in vivo CLL xenograft model. direct apoptotic effects of daratumumab alone or in com- Conclusions: Overall, our data demonstrate the antitumor bination with ibrutinib. In vivo antileukemic activity was mechanisms of daratumumab in CLL; furthermore, we show assessed in a partially humanized xenograft model. The how cotargeting BTK and CD38 lead to a robust anti-CLL influence of CD38 on B-cell receptor (BCR) signaling was effect, which has clinical implications. Introduction ation with other cell surface (and cell-type specific) antigens. On B lymphocytes, CD38 associates with the B-cell receptor (BCR) CD38 is a highly conserved transmembrane type II glycopro- complex [(BCR)/CD81/CD19/CD21] and amplifies signal inten- tein expressed on B lymphocytes and other hematopoietic sity transmitted through the complex to drive cell prolifera- cells (1). Physiologically, CD38 functions as an ectoenzyme and tion (2). Patients with CLL with a higher proportion of CLL cells a coreceptor, the latter depending on its spatiotemporal associ- expressing CD38 (30%) have a shorter time to symptomatic disease and a more aggressive clinical course with inferior survival þ 1Department of Cancer Biology, Mayo Clinic, Jacksonville, Florida. 2Division of versus patients who have <30% of CD38 CLL cells (3, 4), Hematology and Oncology, Mayo Clinic, Jacksonville, Florida. 3Department of thus establishing CD38 expression as a marker of poor progno- Cancer Prevention & Control, Roswell Park Cancer Institute, Buffalo, New York. sis (5, 6). Despite its known association with an aggressive CLL 4Department of Health Science Research, Mayo Clinic, Jacksonville, Florida. phenotype, the role of CD38 as a therapeutic target remains 5 Lab of Immunogenetics, Department of Medical Science, University of Torino, unclear. Italy. 6Signal Transduction Laboratory, Kogod Aging Center, Department of Daratumumab is a first-in-class anti-CD38 therapeutic mAb Anesthesiology, Mayo Clinic, Rochester, Minnesota. 7Mayo Clinic Cancer Center at St. Vincent's Hospital, Jacksonville, Florida. approved for the treatment of relapsed/refractory multiple myeloma (7). It comprises a fully human IgG1k mAb, which Note: Supplementary data for this article are available at Clinical Cancer Research Online (http://clincancerres.aacrjournals.org/). binds the C-terminus of CD38 at an epitope composed of b-strand–containing amino acids 233–246 and 267–280 (8). A fi A. Manna and S. Aulakh contributed equally and are co- rst authors of this report by Matas-Cespedes and colleagues demonstrated the anti- article. leukemic effects of single-agent daratumumab in ex vivo and in vivo Corresponding Authors: Aneel Paulus, Mayo Clinic, 4500 San Pablo Road CLL models (9). The cytotoxicity reported was modest, with South, Jacksonville, FL 32224. Phone: 904-953-6184; Fax: 904-953-6233; partial insight into the direct killing mechanism of daratumumab E-mail: [email protected]; and Asher Chanan-Khan, E-mail: [email protected] in CLL cells. We hypothesized that CD38 is a high value target in CLL and blocking of its receptorial function can be translated Clin Cancer Res 2019;25:3974–85 into a clinically beneficial therapeutic strategy through improved doi: 10.1158/1078-0432.CCR-18-3412 understanding of the mechanism(s) that link CD38 to CLL Ó2019 American Association for Cancer Research. cell survival. Here, we provide evidence that CD38 engagement 3974 Clin Cancer Res; 25(13) July 1, 2019 Downloaded from clincancerres.aacrjournals.org on September 23, 2021. © 2019 American Association for Cancer Research. Published OnlineFirst April 2, 2019; DOI: 10.1158/1078-0432.CCR-18-3412 Daratumumab and Ibrutinib in CLL À and MEC1 (CD38 ) cell lines were also used in experiments. Translational Relevance An in vivo model of disseminated disease (14, 15) was estab- Increased CD38 expression on chronic lymphocytic leuke- lished using luciferase-labeled JVM13 (JVM13-Luc) cells, mia (CLL) cells is linked to aggressive disease features and injected via tail vein intravenously into 6- to 8-week old NSG poor clinical outcome. Biologically, CD38 promotes CLL cell (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) mice, following a proto- proliferation through association with multiple cell surface col approved by the Mayo Clinic Institutional Animal Care and receptors, including the B-cell receptor (BCR). As therapeutic Use Committee. Ibrutinib and kuromanin were purchased from opportunities to disrupt CD38 function become increasingly Selleckchem. Daratumumab was acquired through the Mayo available, we investigated the antitumor activity of daratumu- Clinic pharmacy and came predissolved/diluted. Statistical mab (anti-CD38 human mAb) in patient-derived CLL cells. analyses were performed using R Statistical Software (version Daratumumab was noted to promote immune-effector– 3.2.3; R Foundation for Statistical Computing), further detailed mediated cytolysis, as well as direct apoptosis of CLL cells. in figure legends. Data are represented as mean Æ SEM, unless Inhibition of CD38 (with daratumumab or a small-molecule otherwise stated in the figure legend. inhibitor) decreased activation of BCR signaling proteins and A full description of all assays is presented in Supplementary this effect was enhanced by ibrutinib. In vivo, the combination Materials and Methods. of ibrutinib and daratumumab significantly delayed tumor growth in B-cell leukemia–bearing mice and prolonged their survival. Altogether, our results suggest that combination of Results ibrutinib and daratumumab yields greater anti-CLL activity Patient and sample characteristics than either agent alone and support clinical evaluation of Patients with CLL (n ¼ 36) representing all clinical and genetic this regimen in patients with CLL. subsets were included in the study (clinical characteristics in Supplementary Tables S1 and S2). Relatively consistent with prior þ reports, we noted 27.7% (n ¼ 10) of patients had CD38 disease (using standard 30% cutoff; refs. 16, 17), whereas the remaining À by daratumumab modulates BCR signaling and enhances the patients (n ¼ 26, 72.2%) had CD38 disease. Notably, 16.6% anti-CLL activity of ibrutinib. Our observations provide impor- (n ¼ 6) of patients carried a deletion in chromosome 17p positive tant preclinical evidence for clinical exploitation of CD38 as a (Del17pþ). target for treatment of CLL. Daratumumab induces immune-mediated cytotoxicity in CLL cells Materials and Methods We first investigated the ability of daratumumab to induce Written informed consent wasobtainedfromallpatients CLL-specific lysis through immune-effector mechanisms (ADCC, whose samples were used in this study, approved by the Mayo CDC, and ADCP). Mean specific lysis from ADCC was 17.59% Æ Clinic Jacksonville Institutional Review Board and in accor- 1.30% (Fig. 1A). Subset analysis in CLL cells from patients þ À dance with the Declaration of Helsinki. Peripheral blood was defined as having CD38 and CD38 disease showed significant- þ collected from patients with a confirmed diagnosis of CLL who ly greater ADCC (P ¼ 0.023) in CD38 cases (24.63% Æ 3.46%) À were not on active anti-CLL treatment or those off anti-CLL versus CD38 cases (14.11% Æ 1.11%; Fig. 1B). In flow-sorted þ therapy for 1 month. This was followed by isolation of CD19 /CD38hi clones treated with daratumumab, ADCC was þ þ þ CD19 /CD5 B cells (primary CLL cells). Peripheral blood noted in 22.45% Æ 2.36% of cells. And in CD19 /CD38lo clones, mononuclear cells (PBMC) from human donors were used in ADCC was noted in 16.47% Æ 1.03% of cells (Fig. 1C). We then antibody-dependent cell-mediated cytotoxicity (ADCC) assays, assessed cell death via CDC in all CLL cells (n ¼ 30) and noted that 10% human serum was used in complement-dependent death mean specific lysis, was in the order of 14.88% Æ 0.92% (Fig. 1D). þ (CDC) assays, and human macrophages were used in antibody- Marginally higher levels were observed in CLL cells from CD38 À dependent cellular phagocytosis (ADCP) assays, as described patients (18.22% Æ 2.41%) versus CD38 patients (13.58% Æ by de Weers and colleagues (8). Apoptosis, mitochondrial 0.95%; Fig. 1E). In flow-sorted cells, CDC was noted in 19.10% Æ þ transmembrane permeability, and Western blotting assays were 1.98% and 9.23% Æ 1.81% of CD19 /CD38hi clones and þ conducted as per prior methods (10–13). All cells were cultured CD19 /CD38lo clones, respectively.
Load more

Recommended publications
  • CD38, CD157, and RAGE As Molecular Determinants for Social Behavior
    cells Review CD38, CD157, and RAGE as Molecular Determinants for Social Behavior Haruhiro Higashida 1,2,* , Minako Hashii 1,3, Yukie Tanaka 4, Shigeru Matsukawa 5, Yoshihiro Higuchi 6, Ryosuke Gabata 1, Makoto Tsubomoto 1, Noriko Seishima 1, Mitsuyo Teramachi 1, Taiki Kamijima 1, Tsuyoshi Hattori 7, Osamu Hori 7 , Chiharu Tsuji 1, Stanislav M. Cherepanov 1 , Anna A. Shabalova 1, Maria Gerasimenko 1, Kana Minami 1, Shigeru Yokoyama 1, Sei-ichi Munesue 8, Ai Harashima 8, Yasuhiko Yamamoto 8, Alla B. Salmina 1,2 and Olga Lopatina 2 1 Department of Basic Research on Social Recognition and Memory, Research Center for Child Mental Development, Kanazawa University, Kanazawa 920-8640, Japan; [email protected] (M.H.); [email protected] (R.G.); [email protected] (M.T.); [email protected] (N.S.); [email protected] (M.T.); [email protected] (T.K.); [email protected] (C.T.); [email protected] (S.M.C.); [email protected] (A.A.S.); [email protected] (M.G.); minami-k@staff.kanazawa-u.ac.jp (K.M.); [email protected] (S.Y.) 2 Laboratory of Social Brain Study, Research Institute of Molecular Medicine and Pathobiochemistry, Krasnoyarsk State Medical University named after Prof. V.F. Voino-Yasenetsky, Krasnoyarsk 660022, Russia; [email protected] (A.B.S.); [email protected] (O.L.) 3 Division of Molecular Genetics and Clinical Research, National Hospital Organization Nanao Hospital, Nanao 926-0841, Japan 4 Molecular Biology and Chemistry, Faculty of Medical Science, University of Fukui, Fukui
    [Show full text]
  • Dysregulated CD38 Expression on Peripheral Blood Immune Cell Subsets in SLE
    International Journal of Molecular Sciences Article Dysregulated CD38 Expression on Peripheral Blood Immune Cell Subsets in SLE Marie Burns 1,†, Lennard Ostendorf 1,2,3,† , Robert Biesen 1,2 , Andreas Grützkau 1, Falk Hiepe 1,2, Henrik E. Mei 1,† and Tobias Alexander 1,2,*,† 1 Deutsches Rheuma-Forschungszentrum (DRFZ Berlin), a Leibniz Institute, 10117 Berlin, Germany; [email protected] (M.B.); [email protected] (L.O.); [email protected] (R.B.); [email protected] (A.G.); [email protected] (F.H.); [email protected] (H.E.M.) 2 Department of Rheumatology and Clinical Immunology, Charité–Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and The Berlin Institute of Health (BIH), 10117 Berlin, Germany 3 Department of Nephrology and Intensive Care Medicine, Charité–Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and The Berlin Institute of Health (BIH), 10117 Berlin, Germany * Correspondence: [email protected] † Authors contributed equally to this manuscript. Abstract: Given its uniformly high expression on plasma cells, CD38 has been considered as a therapeutic target in patients with systemic lupus erythematosus (SLE). Herein, we investigate the distribution of CD38 expression by peripheral blood leukocyte lineages to evaluate the potential therapeutic effect of CD38-targeting antibodies on these immune cell subsets and to delineate the use of CD38 as a biomarker in SLE. We analyzed the expression of CD38 on peripheral blood leukocyte subsets by flow and mass cytometry in two different cohorts, comprising a total of 56 SLE patients. The CD38 expression levels were subsequently correlated across immune cell lineages and subsets, Citation: Burns, M.; Ostendorf, L.; and with clinical and serologic disease parameters of SLE.
    [Show full text]
  • CD Markers Are Routinely Used for the Immunophenotyping of Cells
    ptglab.com 1 CD MARKER ANTIBODIES www.ptglab.com Introduction The cluster of differentiation (abbreviated as CD) is a protocol used for the identification and investigation of cell surface molecules. So-called CD markers are routinely used for the immunophenotyping of cells. Despite this use, they are not limited to roles in the immune system and perform a variety of roles in cell differentiation, adhesion, migration, blood clotting, gamete fertilization, amino acid transport and apoptosis, among many others. As such, Proteintech’s mini catalog featuring its antibodies targeting CD markers is applicable to a wide range of research disciplines. PRODUCT FOCUS PECAM1 Platelet endothelial cell adhesion of blood vessels – making up a large portion molecule-1 (PECAM1), also known as cluster of its intracellular junctions. PECAM-1 is also CD Number of differentiation 31 (CD31), is a member of present on the surface of hematopoietic the immunoglobulin gene superfamily of cell cells and immune cells including platelets, CD31 adhesion molecules. It is highly expressed monocytes, neutrophils, natural killer cells, on the surface of the endothelium – the thin megakaryocytes and some types of T-cell. Catalog Number layer of endothelial cells lining the interior 11256-1-AP Type Rabbit Polyclonal Applications ELISA, FC, IF, IHC, IP, WB 16 Publications Immunohistochemical of paraffin-embedded Figure 1: Immunofluorescence staining human hepatocirrhosis using PECAM1, CD31 of PECAM1 (11256-1-AP), Alexa 488 goat antibody (11265-1-AP) at a dilution of 1:50 anti-rabbit (green), and smooth muscle KD/KO Validated (40x objective). alpha-actin (red), courtesy of Nicola Smart. PECAM1: Customer Testimonial Nicola Smart, a cardiovascular researcher “As you can see [the immunostaining] is and a group leader at the University of extremely clean and specific [and] displays Oxford, has said of the PECAM1 antibody strong intercellular junction expression, (11265-1-AP) that it “worked beautifully as expected for a cell adhesion molecule.” on every occasion I’ve tried it.” Proteintech thanks Dr.
    [Show full text]
  • The Enzymatic Activities of CD38 Enhance CLL Growth and Trafficking
    Leukemia (2015) 29, 356–368 © 2015 Macmillan Publishers Limited All rights reserved 0887-6924/15 www.nature.com/leu ORIGINAL ARTICLE The enzymatic activities of CD38 enhance CLL growth and trafficking: implications for therapeutic targeting T Vaisitti1,2, V Audrito1,2, S Serra1,2, R Buonincontri1,2, G Sociali3, E Mannino3, A Pagnani2, A Zucchetto4, E Tissino4, C Vitale5, M Coscia5, C Usai6, C Pepper7, V Gattei4, S Bruzzone3 and S Deaglio1,2 The ecto-enzyme CD38 is gaining momentum as a novel therapeutic target for patients with hematological malignancies, with several anti-CD38 monoclonal antibodies in clinical trials with promising results. In chronic lymphocytic leukemia (CLL) CD38 is a marker of unfavorable prognosis and a central factor in the pathogenetic network underlying the disease: activation of CD38 regulates genetic pathways involved in proliferation and movement. Here we show that CD38 is enzymatically active in primary CLL cells and that its forced expression increases disease aggressiveness in a xenograft model. The effect is completely lost when using an enzyme-deficient version of CD38 with a single amino-acid mutation. Through the enzymatic conversion of NAD into ADPR (ADP-ribose) and cADPR (cyclic ADP-ribose), CD38 increases cytoplasmic Ca2+ concentrations, positively influencing proliferation and signaling mediated via chemokine receptors or integrins. Consistently, inhibition of the enzymatic activities of CD38 using the flavonoid kuromanin blocks CLL chemotaxis, adhesion and in vivo homing. In a short-term xenograft model using primary cells, kuromanin treatment traps CLL cells in the blood, thereby increasing responses to chemotherapy. These results suggest that monoclonal antibodies that block the enzymatic activities of CD38 or enzyme inhibitors may prove therapeutically useful.
    [Show full text]
  • Monoclonal Antibodies in Myeloma
    Monoclonal Antibodies in Myeloma Pia Sondergeld, PhD, Niels W. C. J. van de Donk, MD, PhD, Paul G. Richardson, MD, and Torben Plesner, MD Dr Sondergeld is a medical student at the Abstract: The development of monoclonal antibodies (mAbs) for University of Giessen in Giessen, Germany. the treatment of disease goes back to the vision of Paul Ehrlich in Dr van de Donk is a hematologist in the the late 19th century; however, the first successful treatment with department of hematology at the VU a mAb was not until 1982, in a lymphoma patient. In multiple University Medical Center in Amsterdam, The Netherlands. Dr Richardson is the R.J. myeloma, mAbs are a very recent and exciting addition to the Corman Professor of Medicine at Harvard therapeutic armamentarium. The incorporation of mAbs into Medical School, and clinical program current treatment strategies is hoped to enable more effective and leader and director of clinical research targeted treatment, resulting in improved outcomes for patients. at the Jerome Lipper Myeloma Center, A number of targets have been identified, including molecules division of hematologic malignancy, depart- on the surface of the myeloma cell and components of the bone ment of medical oncology, Dana-Farber Cancer Institute in Boston, MA. Dr Plesner marrow microenvironment. Our review focuses on a small number is a professor of hematology at the Univer- of promising mAbs directed against molecules on the surface of sity of Southern Denmark and a consultant myeloma cells, including CS1 (elotuzumab), CD38 (daratumumab, in the department of hematology at Vejle SAR650984, MOR03087), CD56 (lorvotuzumab mertansine), and Hospital in Vejle, Denmark.
    [Show full text]
  • A Molecular Signature of Dormancy in CD34+CD38- Acute Myeloid Leukaemia Cells
    www.impactjournals.com/oncotarget/ Oncotarget, 2017, Vol. 8, (No. 67), pp: 111405-111418 Research Paper A molecular signature of dormancy in CD34+CD38- acute myeloid leukaemia cells Mazin Gh. Al-Asadi1,2, Grace Brindle1, Marcos Castellanos3, Sean T. May3, Ken I. Mills4, Nigel H. Russell1,5, Claire H. Seedhouse1 and Monica Pallis5 1University of Nottingham, School of Medicine, Academic Haematology, Nottingham, UK 2University of Basrah, College of Medicine, Basrah, Iraq 3University of Nottingham, School of Biosciences, Nottingham, UK 4Centre for Cancer Research and Cell Biology, Queen’s University Belfast, Belfast, UK 5Clinical Haematology, Nottingham University Hospitals, Nottingham, UK Correspondence to: Claire H. Seedhouse, email: [email protected] Keywords: AML; dormancy; gene expression profiling Received: September 19, 2017 Accepted: November 14, 2017 Published: November 30, 2017 Copyright: Al-Asadi et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. ABSTRACT Dormant leukaemia initiating cells in the bone marrow niche are a crucial therapeutic target for total eradication of acute myeloid leukaemia. To study this cellular subset we created and validated an in vitro model employing the cell line TF- 1a, treated with Transforming Growth Factor β1 (TGFβ1) and a mammalian target of rapamycin inhibitor. The treated cells showed decreases in total RNA, Ki-67 and CD71, increased aldehyde dehydrogenase activity, forkhead box 03A (FOX03A) nuclear translocation and growth inhibition, with no evidence of apoptosis or differentiation. Using human genome gene expression profiling we identified a signature enriched for genes involved in adhesion, stemness/inhibition of differentiation and tumour suppression as well as canonical cell cycle regulation.
    [Show full text]
  • ADP-Ribose Or Cyclic ADP-Ribose Independently of Enzymatically
    CD38 Signaling in B Lymphocytes Is Controlled by Its Ectodomain but Occurs Independently of Enzymatically Generated ADP-Ribose or Cyclic ADP-Ribose This information is current as of September 27, 2021. Frances E. Lund, Hélène M. Muller-Steffner, Naixuan Yu, C. David Stout, Francis Schuber and Maureen C. Howard J Immunol 1999; 162:2693-2702; ; http://www.jimmunol.org/content/162/5/2693 Downloaded from References This article cites 39 articles, 19 of which you can access for free at: http://www.jimmunol.org/content/162/5/2693.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 27, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 1999 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. CD38 Signaling in B Lymphocytes Is Controlled by Its Ectodomain but Occurs Independently of Enzymatically Generated ADP-Ribose or Cyclic ADP-Ribose1 Frances E. Lund,2*He´le`ne M. Muller-Steffner,† Naixuan Yu,* C.
    [Show full text]
  • The Functional in Vitro Response to CD40 Ligation Reflects a Different
    Leukemia (2011) 25, 1760–1767 & 2011 Macmillan Publishers Limited All rights reserved 0887-6924/11 www.nature.com/leu ORIGINAL ARTICLE The functional in vitro response to CD40 ligation reflects a different clinical outcome in patients with chronic lymphocytic leukemia This article has been corrected since advance Online Publication, and a corrigendum is also printed in this issue C Scielzo1,2,9, B Apollonio1,3,4,9, L Scarfo` 5,6, A Janus6, M Muzio1,4, E ten Hacken3,6, P Ghia3,6,7,8 and F Caligaris-Cappio1,3,7,8 1Laboratory of Lymphoid Malignancies, Division of Molecular Oncology, Istituto Scientifico San Raffaele, Milan, Italy; 2Unversita` degli studi di Milano, Milan, Italy; 3Universita` Vita-Salute San Raffaele, Milan, Italy; 4Laboratory of cell activation and signalling, Division of Molecular Oncology, Istituto Scientifico San Raffaele, Milan, Italy; 5Haematology Section, University of Ferrara, Ferrara, Italy; 6Laboratory of B Cell Neoplasia, Division of Molecular Oncology, Istituto Scientifico San Raffaele, Milan, Italy; 7Unit of Lymphoid Malignancies, Department of Oncology, Istituto Scientifico San Raffaele, Milan, Italy and 8MAGIC (Microenvironment and Genes in Cancers of the blood) Interdivisional Research Program, Istituto Scientifico San Raffaele, Milan, Italy Malignant B lymphocytes from chronic lymphocytic leukemia who have a poorer clinical outcome and tend to express other (CLL) patients maintain the capacity to respond to CD40 negative prognostic factors (for example, ZAP70 or CD38 ligation, among other microenvironmental stimuli.
    [Show full text]
  • Myeloma NK Cells Are Exhausted and Have Impaired Regulation of Activation
    Letters to the Editor ed by CISH) is a critical negative regulator of IL-15 sig- Myeloma natural killer cells are exhausted and have naling and inhibits cytotoxicity against tumor cells.9 impaired regulation of activation Gene set enrichment analysis (GSEA) revealed genes related to NK-cell activation pathways were significantly Multiple myeloma (MM) is an immunotherapy respon- up-regulated in RRMM patient NK cells compared to HD sive disease. Treatment strategies including immune- NK cells, suggesting that NK cells from patients are con- modulatory drugs lenalidomide and pomalidomide, stitutively more activated (Figure 1C). This finding was bi-specific t-cell engagers (BiTE), and antibodies targeting also true when comparing NK-cell activation pathways myeloma surface proteins SLAMF7 (elotuzumab) or between RRMM patient and HD CD57– NK cells or CD38 (daratumumab and isatuximab) and chimeric anti- CD57+ NK cells (Figure 1C and D). However, genes relat- 1-4 gen receptor T cells have been effective. Currently, ed to pathways regulating NK-cell activation (IL23A, myeloma-targeting antibodies against CD38 and IL23R, GAS6, IL18, IL15, AXL, FLT3LG, TICAM1 and SLAMF7 mediate their effect in part, via natural killer PLDN) were downregulated in CD57+ NK cells from 1,2 (NK) cells as key effectors. However, NK cells from RRMM patients, suggesting dysregulation of patient NK myeloma patients have decreased functional responses to cell activation (Figure 1C and E). GSEA enrichment plots 5 myeloma in vitro. Despite this, myeloma targeting anti- highlight significantly increased MM patient NK-cell acti- bodies that are reliant on NK-cell mediated cytotoxicity vation, yet co-existing suppression of positive regulation 2 have been successful in treating MM patients.
    [Show full text]
  • In Vivo Evaluation of CD38 and CD138 As Targets for Nanoparticle-Based
    Omstead et al. J Hematol Oncol (2020) 13:145 https://doi.org/10.1186/s13045-020-00965-4 RESEARCH Open Access In vivo evaluation of CD38 and CD138 as targets for nanoparticle-based drug delivery in multiple myeloma David T. Omstead1, Franklin Mejia1, Jenna Sjoerdsma1, Baksun Kim1, Jaeho Shin1, Sabrina Khan1, Junmin Wu1, Tanyel Kiziltepe1,3,4, Laurie E. Littlepage2,3 and Basar Bilgicer1,3,4* Abstract Background: Drug-loaded nanoparticles have established their benefts in the fght against multiple myeloma; how- ever, ligand-targeted nanomedicine has yet to successfully translate to the clinic due to insufcient efcacies reported in preclinical studies. Methods: In this study, liposomal nanoparticles targeting multiple myeloma via CD38 or CD138 receptors are pre- pared from pre-synthesized, purifed constituents to ensure increased consistency over standard synthetic methods. These nanoparticles are then tested both in vitro for uptake to cancer cells and in vivo for accumulation at the tumor site and uptake to tumor cells. Finally, drug-loaded nanoparticles are tested for long-term efcacy in a month-long in vivo study by tracking tumor size and mouse health. Results: The targeted nanoparticles are frst optimized in vitro and show increased uptake and cytotoxicity over nontargeted nanoparticles, with CD138-targeting showing superior enhancement over CD38-targeted nanoparticles. However, biodistribution and tumor suppression studies established CD38-targeted nanoparticles to have signif- cantly increased in vivo tumor accumulation, tumor cell uptake, and tumor suppression over both nontargeted and CD138-targeted nanoparticles due to the latter’s poor selectivity. Conclusion: These results both highlight a promising cancer treatment option in CD38-targeted nanoparticles and emphasize that targeting success in vitro does not necessarily translate to success in vivo.
    [Show full text]
  • Immunohistochemical Characteristics Of
    Original Article doi: 10.5146/tjpath.2014.01298 Immunohistochemical Characteristics of Cystic Odontogenic Lesions: A Comparative Study Kistik Odontojenik Lezyonların İmmünohistokimyasal Özellikleri: Karşılaştırmalı Bir Çalışma Ayhan ÖZcaN, İbrahim YAVAN, Ömer GÜNHAN Department of Pathology, Gülhane Military Medical Academy, School of Medicine, ANKARA, TURKEY ABSTRACT ÖZ Objective: Cystic ameloblastoma, keratocystic odontogenic tumor, Amaç: Kistik ameloblastoma, keratokistik odontojenik tümör, dentigerous cyst, and radicular cyst are the most commonly dentijeröz kist ve radiküler kist en sık karşılaşılan kistik odontojenik encountered cystic odontogenic lesions. The aim of this study was lezyonlardır. Çalışmada bu lezyonlarda survivin, E-cadherin, CD138 to investigate the expressions of survivin, E-cadherin, CD138, and ve CD38 ekspresyonları ve bunların potansiyel tanısal kullanımları CD38 in these lesions and their potential diagnostic usage. araştırılmıştır. Material and Method: A total of 20 cases, consisting 5 radicular Gereç ve Yöntem: Çalışma serimiz 5 kistik ameloblastoma, 5 cysts, 5 dentigerous cysts, 5 keratocystic odontogenic tumors and keratokistik odontojenik tümör, 5 dentijeröz kist ve 5 radiküler kist 5 cystic ameloblastomas were included in our series. For all cases, olmak üzere toplam 20 olgudan oluşmaktadır. Bütün olgulara ait sections from the selected blocks were stained against the antibodies seçilmiş bloklardan sağlanan kesitler otomatize bir cihazda survivin, for survivin, E-cadherin, CD138, and CD38 on an automated device. E-cadherin, CD138, and CD38 antikorları ile boyandı. Results: All cystic ameloblastomas and keratocystic odontogenic Bulgular: Kistik ameloblastoma ve keratokistik odontojenik tumors showed diffuse and strong nuclear survivin expression. tümörlerin hepsi yaygın ve kuvvetli nükleer survivin ekspresyonu No specific survivin immunoreactivity was observed in the gösterdi. Dentijeröz ve radiküler kistlerde spesifik survivin dentigerous and radicular cysts.
    [Show full text]
  • Multi-Antigen Imaging Reveals Inflammatory DC, ADAM17
    International Journal of Molecular Sciences Article Multi-Antigen Imaging Reveals Inflammatory DC, ADAM17 and Neprilysin as Effectors in Keloid Formation Mathias Rath 1 , Alain Pitiot 2, Michael Kirr 3,4,5, Waltraud Fröhlich 3,4,5, Bianca Plosnita 6, Stefan Schliep 3,4,5, Jürgen Bauerschmitz 3,4,5, Andreas S. Baur 3,4,5 and Christian Ostalecki 3,4,5,7,* 1 Department of Urology, University Hospital Heidelberg, 69120 Heidelberg, Germany; [email protected] 2 Laboratory of Image & Data Analysis, Ilixa Ltd., London W1U 6NQ, UK; [email protected] 3 Department of Dermatology, Universitätsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg, 91054 Erlangen, Germany; [email protected] (M.K.); [email protected] (W.F.); [email protected] (S.S.); [email protected] (J.B.); [email protected] (A.S.B.) 4 Deutsches Zentrum Immuntherapie (DZI), 91054 Erlangen, Germany 5 Comprehensive Cancer Center (CCC) Erlangen, 91054 Erlangen, Germany 6 TissueGnostics GmbH, 1020 Vienna, Austria; [email protected] 7 Department of Psychiatry and Psychotherapy, Universitätsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg, 91054 Erlangen, Germany * Correspondence: [email protected]; Tel.: +49-9131-8532965 Abstract: Keloid is an aberrant scarring process of the skin, characterized by excessive extracellular matrix synthesis and deposition. The pathogenesis of this prevalent cutaneous disorder is not fully understood; however, a persistent inflammatory process is observed. To obtain more insight into Citation: Rath, M.; Pitiot, A.; Kirr, M.; this process, we analyzed lesional, perilesional and healthy tissue using multi-antigen-analysis Fröhlich, W.; Plosnita, B.; Schliep, S.; (MAA) in conjunction with a data mining approach.
    [Show full text]